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KAJIANTENTANG POTENSI ANTIVIRAL MADU TUALANG 
TERHADAP JANGKITAN VIRUS CHIKUNGUNYA IN VITRO DI 





Chikungunya adalah penyakit virus bawaan nyamuk yang ditularkan kepada 
manusia oleh CHIKV dan ia telah menjejaskan banyak negara di seluruh dunia. 
CHIKV disebarkan oleh dua spesies utama nyamuk Aedes, Aedes aegypti dan Aedes 
albopictus dan kebiasaannya menyebabkan  penyakit akut dengan demam, ruam, dan 
artralgia. Pada masa ini, tiada antivirus atau vaksin yang tersedia secara komersil. 
Dalam kajian ini, kami menyelidik aktiviti antivirus madu Tualang terhadap CHIKV 
dalam sel Vero. Potensi sifat anti-CHIKV madu Tualang dalam assai yang berbeza, 
virusid, pra-rawatan, pasca rawatan, anti-kemasukan dan anti-penjerapan, 
menggunakan kepekatan madu Tualang yang tidak toksik pada waktu inkubasi yang 
berbeza. Kesan perencatan virus dinilai dengan memerhatikan perubahan morfologi 
sel Vero yang selanjutnya disahkan oleh assai plak. Hasil penyelidikan ini 
menunjukkan bahawa madu Tualang tidak menjadi toksik kepada sel Vero apabila 
digunakan pada kepekatan antara 20 mg/mL hingga 5 mg/mL. Kajian ini juga 
menunjukkan bahawa madu Tualang mempamerkan aktiviti antivirus yang signifikan 
terhadap CHIKV. Aktiviti virusid madu Tualang terhadap jumlah/kuantiti CHIKV 
yang berbeza menunjukkan perencatan yang signifikan pada titer virus. Menariknya, 
pra-rawatan madu Tualang terhadap sel Vero selama 12 dan 24 jam    sebelum 
jangkitan telah memberi kesan perencatan tertinggi pada replikasi CHIKV terutama 
48 jam selepas jangkitan, dengan kira-kira 90% perencatan titer virus dicatatkan (P 
<0.05). Tambahan lagi, semasa assai pasca rawatan, replikasi CHIKV telah 
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direncatkan secara signifikan di dalam sel Vero selepas pasca pendedahan pada madu 
Tualang selama 8 jam. Rawatan pasca sel dengan madu Tualang menunjukkan kesan 
pengurangan titer virus adalah paling besar apabila dibandingkan dengan assai lain 
dengan peratusan perencatan sebanyak 98% (P <0.05). Walau bagaimanapun, madu 
Tualang tidak merencat jangkitan CHIKV di dalam sel Vero semasa assai anti- 
penjerapan dan anti-kemasukan dengan peratus perencatan hanyalah 33 hingga 80%. 
Secara keseluruhannya, hasil dari kajian semasa menunjukkan bahawa madu Tualang 
mempunyai potensi untuk dikembangkan sebagai agen alternatif anti- CHIKV. 
Kajian masa depan adalah wajar untuk menjelaskan mekanisme tindakan madu 
Tualang dan sama ada kesan yang sama dapat ditunjukkan secara in vivo. 
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 Chikungunya is a mosquito-borne viral disease transmitted to human by CHIKV 
which has affected many countries around the world.   CHIKV is transmitted mainly by 
two species of Aedes mosquitoes, Aedes albopictus and Aedes aegypti, and causes 
typically acute illness with incapacitating arthralgia, fever and rashes. Currently, there is 
no antiviral or licensed vaccine commercially available. In this study, we explored the in 
vitro antiviral activity of the Tualang honey against CHIKV in Vero cells. The potential 
anti-CHIKV property of Tualang honey was determined in different assays including 
virucidal, pre-treatment, post-treatment, anti- entry and anti-adsorption, using the non-
toxic concentrations of Tualang honey at different incubation hours. The viral inhibitory 
effect was confirmed by plaque assay after morphological changes of Vero cells were 
observed. The results showed that Tualang honey was not toxic to Vero cells at 
concentration between 20 mg/mL to 5 mg/mL. This study demonstrated that Tualang 
honey exhibited significant antiviral activity against CHIKV. The virucidal activity of 
Tualang honey against different amounts of CHIKV was observed by the significant 
inhibition noticed in the viral titre. Remarkably, the pre-treatment of Tualang honey on 
Vero cells for 12 and 24 hours before infection gave the highest inhibitory effect on 
CHIKV especially at 48 hours post infection, with about 90% inhibition of viral titres 
was observed (P < 0.05). Surprisingly, during post-treatment assay, CHIKV replication 
was significantly inhibited in Vero cells following post-exposure to Tualang honey for 
8 hours. The post-treatment of cells with Tualang honey displayed the biggest reduction 
of viral titre effect when compared with the other assays with percentage of inhibition 
xv  
98% (P < 0.05). However, Tualang honey did not significantly inhibit infection of Vero 
cells by CHIKV during the anti-adsorption and anti-entry assay with percentage of 
inhibition surpassed 33 to 80%. Overall, the results from the current study suggest that 
Tualang honey can be explored as an alternative anti-CHIKV agent. Future study is 
warranted to elucidate Tualang honey mechanism of action and whether similar effects 






1.1 Chikungunya virus 
 
Chikungunya virus (CHIKV) was initially described by W.H.R. Lumsden and M. 
Robinson in 1955 after the outbreak along the border between Tanganyika and 
Mozambique (which is currently a part of Tanzania) in 1952 (Amar & Vilhekar, 
2015). The virus was found in the serum of an infected patient in Makonde Plateau 
(Silva & Dermody, 2017). CHIKV belongs to the Togaviridae family, and the 
Alphavirus genus (Furuya et al., 2016). It has a capsid with 60-70 nanometres 
diameter, a phospholipid envelope and a single stranded positive sense RNA genome 
(Figure 1.1) (Cunha & Trinta, 2017). The CHIKV particle has icosahedral spherical 
structure with triangulation number (T) equals 4 symmetry structure of the virus. The 
structure contains 80 spikes including 20 icosahedral “i3” spikes that are situated on 
the icosahedral 3-fold axes and 60 quasi-3-fold “q3” spikes with quasi-3-fold axis 
(Nguyen et al., 2018). The CHIKV genome is approximately 12,000 nucleotides 
(Carletti et al., 2017).  
 
The first reading frame (ORF1) encodes for a polyprotein and acts as a precursor of 
the non- structural proteins (NS1, NS2, NS3 and NS4), while the second reading 
frame (ORF2) encodes the structural proteins (capsid proteins, assembly proteins E3, 
envelope glycoproteins E2, 6K protein and envelope glycoproteins E1 (Figure 1.2) 
(Jain et al., 2017). 
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Structural proteins result from a cleavage of polyprotein by signalase and auto 
proteinase. Additionally, structural proteins such as envelope glycoprotein- E1 and 
E2 have been shown to mediate viral entry hosts (Wong & Chu, 2018). Similarly, 
non-structural proteins play crucial roles during virus replication, protein 
modification, and immune antagonism (Nguyen et al., 2018). Mutations that occur in 
the E1 glycoprotein have received significant attention lately because it has been 
understood that the mutations modifies the virus’s ability to infect mosquitoes and 
increase severity of the illness in affected persons (Bordi et al., 2015).  
 
The enhanced infectiousness and transfer of the virus by Aedes albopictus is due to 
the adaptative mutation of CHIKV to Aedes albopictus mosquito in the envelope 
glycoproteins E1 surface gene (Abdelnabi et al., 2017). Berry et al., (2018) observed 
that Aedes aegypti adaptive strain carrying the E1:K211E and E2:A264V mutations 
is capable of rapid spread in Aedes aegypti rich regions. These strains were found to 
be implicated in explosive outbreaks in some Asian and African countries. Therefore, 
mutated strains have the potential to completely replace the wild type strain and 












Figure 1.1 Viral morphology of CHIKV showing the orientation of the E2 and E1 envelope 















Figure 1.2 Arrangement of CHIKV genome (adopted from Jain et al., 2017). 
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1.2 CHIKV replication 
 
The positive-sense RNA genome of CHIKV encodes four nonstructural proteins (nsP 
1-4) that allow CHIKV replication and transcription complex (Rausalu et al., 2016; 
Remenyi et al., 2018). The genome’s two open reading frame has a 5′ untranslated 
regions and 3′ untranslated regions (UTRs) with a non-coding intergenic region 
separating the two UTRs. The 5′ UTRs has a 5′ type-0 N 7-methylguanosine cap 
which allows cap-dependent translation to be initiated. According to Kendall et al. 
(2019) The 5′ UTRs has a novel element which is very important for CHIKV 
replication in host cells even though replication of positive-sense RNA virus 
genomes is initiated at the 3′ end of the molecule. On the other hand, CHIKV RNA 
synthesis occurs when distinct modules of the viral replicase complexes formed as a 
result of ORF-1 encoding nsP 1-4 (Kendall et al., 2019).  
 
As replication of the genomic positive-sense RNA to full length negative–sense 
intermediates progresses, proteolytic processing of the non-structural protein 
precursors in the replicase complex occurs and therefore allows its association with 
the negative-strand and subsequent replication of positive-sense full-length genomic 
transcripts (Kallio et al., 2016). Meanwhile, ORF-2 transcripts encoding structural 
proteins (in the negative strand) are synthesised from a sub-genomic promoter in the 
negative strand (Kendall et al., 2019). When infection with CHIKV occurs, 
translation of genomic mRNA into non-structural precursor protein occurs with the 
aid of the cellular and viral proteases (Henss et al., 2018). Additionally, nsP 1-4 also 
plays crucial roles in the synthesis of a minus-sense RNA from the globin mRNA 
(gmRNA), resulting in double-stranded RNA intermediates.  
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These RNA intermediates then activate dsRNA-dependent protein kinase that 
phosphorylates while inactivating the initiation of factor 2 alpha (eIF2α) translation 
(Henss et al., 2018). Therefore, the minus-sense RNA is a template for the synthesis 
of subgenomic mRNA (sgmRNA) and the gmRNA. The structural proteins on the 
other hand are translated from the sgmRNA in an eIF2α-independent manner, 
whereas the synthesis of nsPs requires active eIF2α (Henss et al., 2018). The minus-
strand RNA synthesis is the minus-strand is limited between 3 and 4 hours post 





1.3 Disease burden of chikungunya 
 
The disease burden for chikungunya exists in both individuals and affected 
localities/countries (Fritzell et al., 2018). Reduced productivity, extra health care 
costs and associated co-morbidities cause a huge burden on individuals, public 
healthcare systems and communities (Alvis et al., 2018; van et al., 2017). Severity of 
CHIKV infection has been observed in children and elderly (above 60 years) and 
mortality cases recorded maybe underestimated considering CHIKV confirmatory 
diagnosis are not carried in certain countries due to limited resources and similarities 
of chikungunya to dengue fever (Yapa et al., 2019). Since chikungunya may present 
with cerebral disorders such as encephalopathy, altered mental status and disrupted 
behaviour, the severe cases of CHIKV infection affects quality of life of infected 
persons (Mehta et al., 2018).  
 
Burt et al. (2017) reported that two years after acute CHIKV infections, about 43% 
to 75% of infected persons experienced either late-onset of symptoms or prolonged 
symptoms which consequently meant that they suffered long-term health 
implications (as the disease burden can last up to 3 years). 
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Rahim et al. (2016) study also showed that persistent pain was experienced in some 
individuals 18 months after CHIKV infection. Additionally, Rodriguez et al. (2016) 
reported that post-chikungunya chronic arthritis was observed in about 14% of 
patients with CHIKV infection. Additionally, their studies revealed that the risk of 
developing chronic inflammatory rheumatism post chikungunya infection increases 
in elderly people, women and patients with multiple comorbidities. Therefore, 
disease burden as a result of CHIKV infection can have an impact on national 
development, business, public health, individual and even household costs (Alvis et 
al., 2018).  
 
An example of national development costs implications due to CHIKV infection is 
seen in the Caribbean countries where revenue loss from tourism was reported. 
Reduced workforce productivity can also affect business costs in relation to sick time 
or modified workload assignments. Individual costs as a result of CHIKV infection 
could be as a result of costs incurred from purchasing materials for personal 
prevention of vector-borne illnesses, loss of wages, cost of treating CHIKV infection 
or cost of morbidity management. This can lead to financial burden on individuals 
and their families and companies (Rezza & Weaver, 2019). Disease burden can be 













In Rome, the economic burden was estimated at 322,000 euros (EUR) with a loss of 
341 DALYs (Manica et al., 2017). In 2014, the burden of chikungunya in Latin 
America was estimated to be about 151,031–167,950 DALYs lost, or 0.39 DALYs 
per case (as that 45.1–50.1% of 855,890 acute CHIKV cases developed chronic 
inflammatory rheumatism) (Bloch, 2016).  
 
In Colombia, the estimated total costs of CHIKV infection was US$67 million. 
Median of direct medical cost was about US$258 for children while for adults it was 
about US$67. The productivity loss median expenditures were estimated to be up to 
US$81 for each adult patient. While the economic cost in adults was about US$153, 
of which over 50% was as a result of indirect costs. Similarly, out-of-pocket 
spending was estimated to be about 3% of all economic costs (Alvis et al., 2018). 
Therefore, CHIKV infection is global problem that requires the attention of different 
stakeholders to prevent further disease burden. 
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1.4 Ecology and epidemiology of CHIKV 
 
CHIKV infection was first identified in Africa during on outbreak in 1952 and its 
emergence recently in the Caribbean, Americas, Australia, Europe and the Indian 
subcontinent has raised serious concern about the disease (Sanyaolu et al., 2016). 
Musso et al. (2018) reported that since the year 2000, the epidemiology of CHIKV 
has changed from hypoendemic (one serotype) to hyperendemic (multiple serotype 
cocirculation). Three CHIKV genotypes have been identified- Two African strains ( 
i.e the West African and the East Central-South Africa (ECSA) strain), and one 
Asian strain (Mudurangaplar & Peerapur, 2016). However, Arankalle et al. (2007) 
studies showed that the West African, Asian and ECSA strains are closely related, 
with amino acid similarity of 95.2%–99.8%. An increasing number of cases from 
CHIKV infection has been reported globally (Ching et al., 2017; Matusali et al., 
2019).  
 
In the African continent, about 75% of the population was infected with CHIKV 
during the 2004 outbreak in Lamu Island, Kenya in 2004. In 2016, re- emergence of 
CHIKV was observed where about 1,792 cases of CHIKV outbreak was reported in 
Mandera, Kenya. Out of these cases, about 50% of health care workers were affected 
(Berry et al., 2018). 
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At the same time, the neighboring Bula Hawa, Mogadishu, Somalia was also 
affected. This cross-border outbreak expands globally (Ching et al., 2017; Leta et al., 
2018; Monaghan et al., 2018). Increased spread of CHIKV to regions with lower 
temperatures have also been witnessed (Weaver & Forrester, 2015).  
 
Similar to Mandera, Kenya, in Karachi, Pakistan, an outbreak of CHIKV occurred in 
2011 with re-emergence in 2016 where an estimated 30,000 people were infected. As 
Karachi city lies on the coast of the Arabian Sea and houses South Asia’s largest 
cargo port, serious concerns were raised that CHIKV infection might spread to other 
neighbouring countries through freight transport thereby increasing the virus 
abundance in the Asian continent (Rauf et al., 2017). Similar to studies by Rauf et 
al., (2017), Yapa et al., (2019) also documented that chikungunya viral spread has 
expanded its geographic reach in the Asian region since 2005 onwards.  
 
In Malaysia, outbreaks were limited until 2007 when over 10,000 cases were 
reported between 2008 and 2010 (Jesse & Benjamin, 2014). Furthermore, about 50 
cases of CHIKV infection were identified between February and March in the year 
2017 with infected patients exhibiting symptoms such as conjunctivitis, fever, joint 
pains, headaches and rashes. This makes CHIKV infection a significant health 





According to a review by Yapa et al., (2019) and Kaur et al., (2017), India has 
experienced the highest burden high attack rate of CHIKV, accounting for the 
greatest number of reports as it affected billions and declared a major public 
health issue since the first incursion of the virus into South East Asia. In a study by 
Kaur et al., (2017), 97% of patients out of 600 patient’s samples experienced 
swelling, rashes, itching, restricted movement of the joints such as the hands, wrist, 
knees and feet and neurologic complications due to CHIKV infection.  
 
In the Americas, explosive outbreaks and subsequent spread to several continental 
American countries have resulted in more than one and a half million suspected 
cases (Fox & Diamond, 2016) since the first case was detected in 2013 in Saint 
Martin in the Caribbean (Diaz et al., 2015). Autochthonous transmission of the virus 
has been confirmed in 43 countries/territories in South America, North America, 
Central America and the Caribbean (Pham et al., 2017). La Réunion island in the 
Indian Ocean experienced over 250,000 cases of CHIKV infection during a 
seventeen-month long outbreak in 2005-2006 and about 254 deaths were recorded 
(Tjaden et al., 2017; Venturi et al., 2017). 
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Additionally, in La Reunion Island, new clinical forms of CHIKV infection such as 
severe cutaneous effects and acute hepatitis, respiratory, kidney and cardiovascular 
failure, meningoencephalitis and other central nervous system (CNS) problems were 
observed in patients (Gerardin et al., 2016).  
 
Italy for the first time experienced an outbreak in 2007 in the north east of the 
country, near the Adriatic coast, in the province of Ravenna and over 200 cases were 
reported (Marano et al., 2017). Subsequently, in 2010 and 2014 autochthonous cases 
(linked to imported cases), were detected in the city of Montpellier and Var 
department in France (Venturi et al., 2017). In 2017, CHIKV outbreak also saw a 
cluster of locally acquired cases consisting of four confirmed and one probable case 
described again from the Var department in France (Vairo et al., 2018).  
 
Similarly, near Anzio, a coastal town in the province of Rome being a holiday resort, 
witnessed about 179 imported cases of CHIKV (ECDC, 2017). Ciocchetta et al. 
(2018) also reported that a new Aedes mosquito species, Aedes (Finlaya) Koreicus 
which had not been previously reported was observed in Europe during outbreaks. 
This brought to limelight the need to understand the vector potential of invading 
mosquitoes so as to prevent re-emergence of CHIKV infection. 
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In Oceania/Pacific Islands, CHIKV infection emerged in New Caledonia in 2011. 
This subsequently spread throughout the south and central Pacific (Musso et al., 
2018). Other Islands that were also affected by CHIKV includes Cook Islands, 
Tonga, Kiribati, French Polynesia, Papua New Guinea, Samoa, Tokelau, American 
Samoa and Federal States of Micronesia (Petersen & Powers, 2016). A summary of 
some epidemiological findings and implicated genotypes in different parts of the 
world is presented in Table 1. 
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Table 1: Epidemiological findings, implicated genotypes from different countries 
 
 
Genotype Country Epidemiological findings 
ECSA and Asian Bangladesh In 2011, first outbreak was reported 
(almost 30% prevalence rate). 
In 2014, six confirmed cases was 
 
witnessed (after re-emergence) 
ECSA Malawi First outbreak between 1987-1989. 
 
Few cases in 2001 and 2015. 
Asian and ECSA Cambodia The first case was in 1961. Re- 
emergence occurred in 2011 when 
about 24 patients had positive RT- 
PCR and ELISA. 
In 2012, about 45% seroprevalence 
rate was recorded during an outbreak 
in Trapeang Roka Kampong Speu. 
. 
ECSA/Asian Thailand Over 40,000 suspected cases were 
recorded in the 1960s. 
In 1962, over 30% of the population 
was affected during the Bangkok 
outbreak. 
In 2008, 244 cases were confirmed. 
 
In 2013, Bueng  Kan  was  severely 
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  affected during an outbreak. 
ECSA/Asian Singapore In 2008, the first outbreak was 
reported (about 1000 cases) 
Re-emergence occurred in 2013. 
ECSA Laos In 2012, 31 confirmed cases from 
Champassak Province 
An outbreak of CHIV and dengue 
 
was again reported. 
Asian/ECSA Aruba An outbreak occurred in 2014 
 
(estimated cases was over 203). 
Asian Cayman Island In 2014 about 25 cases was reported. 
Re-emergence occurred in 2015 and 
2016. 
Asian/ECSA Martinique 30,715 cases were confirmed in 2013 
(with an incidence rate was 76 per 
1000) 
Asian Colombia In 2014, over 22,300 cases were 
recorded. 
In early 2015, 1,317 cases were 
 
documented. 
Asian/ECSA Venezuela 2303 and 3107 confirmed cases were 
reported in 2015 and 2016, 
respectively. 
Asian/ECSA Argentina 21   and   55   confirmed   cases were 
 
reported in 2015 and 2016, 
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  respectively 
Asian/ ECSA French Guiana Estimated cases in early 2014 was 
over 7,000 
Local transmission also occurred in 
2015, and 2016. 
Asian Japan In 2010, an imported case was 
recorded 
In 2013, 14 confirmed cases were 
recorded (traced to autochthonous 
transmission from a traveller into the 
country) 
Asian/ECSA El Salvador In 2014, about 123,339 cases were 
documented. 
In 2016, almost 6,000 cases was 
 
documented. 
Adopted from Wahid et al., 2017. 
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The different genotypes have spread drastically over the past 20 years (Smalley et 
al., 2016). Globalisation of travel and trade has contributed to the spread of CHIKV 
infections (Therrien et al., 2016; Cella et al., 2018). The sharp rise in the number of 
CHIKV infections from 2004 to 2008 indicated the ease of spread of this viral 
disease in humans (Faria et al., 2016). The probability of global spread is thus 
alarming, increasing and challenging especially with the number of unpredicted 
cases that have emerged (Matusali et al., 2019; Souza et al., 2019). Therefore, 
measures must be taken to improve prevention, screening of travellers from endemic 
countries and control of the disease (Roiz et al., 2018). Figure 1.3 shows the global 






















Figure 1.3 Global distribution of CHIKV infection as of May 2018 
(Adopted from CDC, 2018) 
20  
1.5 Laboratory Diagnosis 
 
Diagnosis of chikungunya infection is likely in individuals who have recently 
travelled to endemic countries and are exhibiting acute or abrupt onset of high fever 
(> 39 °C and lasts 3-5 days), joint pains (past weeks to months) and polyarthralgia 
(Johnson et al., 2016; Wahid et al., 2017). CHIKV infection is detected in addition to 
other clinical signs and symptoms through a blood test. Several important diagnostic 
tool used in CHIKV detection such as RT-PCR, Enzyme-Linked Immunosorbent 
Assays (ELISA) and lateral flow rapid test. RT-PCR is usually very sensitive and 
specific and hence very useful in early detection (Priye et al., 2017). ELISA test is 
particularly important because antibodies in infected patients usually develop by the 
end of the first week, so if RT-PCR is negative, the infection may still be detected 
with the convalescent phase sample (Dinkar et al., 2018). While rapid diagnostic test 
is better emergency testing and helps for detect both anti- CHIKV Immunoglobulin 
























1.6 Pathogenesis of CHIKV 
 
CHIKV infection transmitted by infected mosquitoes can cause different clinical 
manifestations. Viral load in patients can be as high as 1010 virus particles per 
milliliter of blood during the first days of infection and erythematous maculopapular 
or morbilliform eruption can occur (although may subside without any sequelae) in 
3–4 days (Gasque et al., 2016). This eruption could then be a hallmark of an 
inflammatory response of the skin (the portal of entry of CHIKV after the infected 
mosquito bites) to mobilize resident cells such as dermal fibroblasts, melanocytes 
and keratinocytes (Gasque et al., 2016). CHIKV infection prompts immune 
response which leads to the production of interferon type I and interferon-stimulated 
genes, recruitment of innate and adaptive immune cells, and development of 
neutralising antibodies (Fox & Diamond, 2016).  
 
High titres of CHIKV are present in blood samples of infected persons through the 
acute phase and remains high during the chronic phase as well. As a result, 
inflammatory response coincides with rise of immune mediators and infiltration of 
immune cells into infected tissues and joints (Burt et al., 2017). Different 
concentration of chemokines and cytokines is observed in acute and/or chronic 
CHIKV infection (depending on the stage of the infection) (Michlmayr et al., 2018).
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High concentrations of several chemokines such as IP-10 and monocyte 
chemoattractant protein and proinflammatory cytokines such as interferon α, 
interferon γ, IL-6 and anti-inflammatory cytokines such as interleukin 1 receptor 
antagonist, IL-4, IL-Ra, IL-2R, IL-7, IL-8, IL-10, IL-12 and IL-15 have been 
reported (Goupil, 2016). 
 
The alterations in cytokines during the acute stage of the infection have been 
observed (Goupil, 2016). While some cytokines are correlated with disease severity, 
others are correlated specifically with higher viral load (Piedra et al., 2017). Lee et 
al. (2015) study showed that regulatory T cells (Tregs) (a distinct subset of CD4+ T 
cells) prevent exacerbated proinflammatory responses by maintaining tolerance and 
restoring immune homeostasis during inflammatory responses. In line with Lee et al. 
(2015) studies, Burt et al. (2017) showed that circulating activated and effector T 
cells also increased in patients with persistent chikungunya induced arthritis. Studies 
in mice using the established juvenile mice model revealed that depletion of 
regulatory T cells worsened disease pathology while acute loss of T cells resulted in 




1.7 Control strategies of CHIKV 
 
Because outbreaks caused by CHIKV has continued and expanded globally and there 
are no licenced vaccines or antiviral treatments for this debilitating infection, control 
strategies have been developed to treat infections (Chan et al., 2016; Giancotti et al., 
2018; Subudhi et al., 2018). Current treatment has mainly been focused on 
symptomatic relief and hence the need for further investigation (Ganesan et al., 
2017). A discussion of some anti-CHIKV control measures and strategies of 





CHIKV vaccines have been developed to serve as preventative and curative 
measures during epidemics (Erasmus et al., 2016). Ramsauer & Tangy (2016) 
carried out an investigation on anti-CHIKV vaccines using the viral-vector 
technologies. They utilised vectors, for example altered immunization virus Ankara, 
complex adenovirus, alphavirus-based chimeras, vesicular stomatitis and measles 
immunization Schwarz strain in animal models as potential vaccines. They observed 
that full envelope gene cassette or the entire open reading frame expressing the 
structural genes yielded the most-effective and most-protective vaccine promising 
candidates and therefore concluded that virus-vector vaccines show  promising 
results as potential CHIKV vaccine because they induce humoral and cellular 
immune responses using highly attenuated and safe vaccine backbones (Ramsauer 
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& Tangy, 2016). Aside from the viral-vector technologies, anti-CHIKV recombinant 
vaccines have been developed in modified Chinese Hamster Ovary (CHO) cells. Eldi 
et al. (2017) developed a Sementis Copenhagen Vector (SCV) vaccine against 
CHIKV (SCV-CHIK) and used in a range of human cell lines and in 
immunocompromised mice. In mice model, a single immunisation with SCV- 
CHIKV induced antibody responses specific for CHIKV thus neutralising the virus. 
In addition, SCV vaccine was also observed to prevent viremia and arthritis in mice 
model. Anti-CHIKV vaccine (MV-CHIK and VLP) that have advanced to phase I 
clinical trials have also been developed (Tharmarajah et al., 2017). 
 
MV- CHIKV vaccine is a recombinant measles virus vaccine that expresses CHIKV 
surface proteins from the ECSA CHIKV strain. During pre-clinical trials, mice 
models were protected from lethal doses of CHIKV upon being administered with 
the MV-CHIKV vaccine (Tharmarajah et al., 2017). Similar to MV-CHIKV, the 
Virus-like particle (VLP) vaccine, VRC-CHKVLP059-00-VP also protected mice 
models and non-human primates from lethal doses of the ECSA strain of CHIKV 
during preclinical trials although this vaccine is not suitable for long term immunity 
due to the fact that it could enhance reactogenicity, impair tolerability of the vaccine 
and therefore increase production cost of the VLP vaccine (Tharmarajah et al., 
2017). 
